Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T18:22:15.637Z.
Calculation as of: 2026-10-06T18:22:15.637Z.
Quote observation: 2026-10-06T18:19:41.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 82cee4a6010f8650e239c44e6fa86f6cad5a1cacb0b867e980d6d40a64789328
PE RATIO
N/A
Market Cap
$235.97M
PE Ratio
22.59
TTM Avg
18.71
3Y Avg
16.51
5Y Avg
18.62
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Nautilus Biotechnolgy, Inc. (NAUT) | $234.79M | N/A | N/A | N/A | N/A |
| SIGA Technologies, Inc. (SIGA)vs › | $234.90M | N/A | 10.01 | 8.82 | 11.38 |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $237.21M | N/A | N/A | N/A | N/A |
| InflaRx N.V. (IFRX)vs › | $234.93M | N/A | N/A | N/A | N/A |
| Utah Medical Products, Inc. (UTMD)vs › | $235.97M | 22.59 | 18.71 | 16.51 | 18.62 |
| BioAge Labs Inc. (BIOA)vs › | $232.67M | N/A | N/A | N/A | N/A |
| Akebia Therapeutics, Inc. (AKBA)vs › | $237.35M | N/A | N/A | N/A | N/A |
| High Tide Inc. (HITI)vs › | $237.69M | N/A | N/A | N/A | N/A |
| MacroGenics, Inc. (MGNX)vs › | $231.69M | N/A | 28.08 | 28.08 | 28.08 |
| Biodesix, Inc. (BDSX)vs › | $231.57M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$1.84
Forward EPS (Est.)
$-0.51
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
